PPT-Lopinavir -RTV + NVP +

Author : thomas | Published Date : 2023-07-08

2 NRTIs in TreatmentExperienced M97765 Trial Lopinavir RTV Nevirapine 2 NRTIs in TreatmentExperienced M97765 Study Design Source Benson CA et al J Infect

Presentation Embed Code

Download Presentation

Download Presentation The PPT/PDF document "Lopinavir -RTV + NVP +" is the property of its rightful owner. Permission is granted to download and print the materials on this website for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.

Lopinavir -RTV + NVP +: Transcript

2 NRTIs in TreatmentExperienced M97765 Trial Lopinavir RTV Nevirapine 2 NRTIs in TreatmentExperienced M97765 Study Design Source Benson CA et al J Infect Dis 2002185599607. HIV Malaria Co-infection. M . Lamorde. MRCP, PhD. Malaria: major cause of morbidity and mortality in tropics. Treatment: artemisinin derivatives are critical for eradication of . plasmodium falciparum . in pregnancy: . . preterm delivery rates, . infant outcomes and . virological efficacy.. Dr Melissa Perry. Guy’s & St Thomas’ NHS Foundation Trust. London. United Kingdom. Low rates of mother-to-child transmission of HIV . TARV. JHÓSEP ANDRÉS BLANCO MEJÍA. Interno Junior Farmacología Clínica. Universidad de La Sabana. CONTENIDO. Presentación de caso clínico. Consideraciones . farmacoterapéuticas. Recomendaciones. M. edications. in . Paediatrics. Dr Leon J. Levin. Head - . Paediatric. HIV . Programmes. Right to Care. New Regimens for DOH and Private Sector in SA. . 0-3 years. >3years and >10 kg. . 1. Data expressed as mean (n=3) ± SD. . RTV: ritonavir; LPV: . lopinavir. ; ATV: . atazanavir. . . *. *. †. †. *. *. †. †. †. Figure 2. Lipid accumulation in differentiating 3T3-F442A (A) and primary human adipocytes (B) following incubation with protease inhibitors with/without . Paul Reynolds, PharmD, BCCCP. Matthew Miller, PharmD, BCIDP. Gina Moore, PharmD, MBA. March 20, 2020. Learning Objectives. Identify the unique clinical and epidemiological characteristics of Coronavirus (COVID-19) in the spectrum of viral clinical illnesses and previous Coronavirus (SARS, MERS) and non-Coronavirus (influenza, common cold) related illnesses. AI424-043 . Study. Atazanavir vs. Lopinavir-ritonavir in Previous PI Failure . AI424-043. : Study Design. Source: . Cohen C, et al. . Curr Med Res Opin. . 2005;21:. 1683-92.. Atazanavir 400 mg once daily + 2 NRTIs. Lopinavir. -RTV in Treatment Experienced. TITAN Trial. Darunavir/. r . versus Lopinavir/r in Treatment-Experienced . TITAN. : Study Design. Source: . Madruga. JV, et al. Lancet. 2007;370:49-58. . Darunavir. R. itonavir to Raltegravir. SWITCHMRK 1 & 2 Trials. Switching from Lopinavir-Ritonavir to Raltegravir. SWITCHMRK 1 & 2 Trials: Study Design. Source: . Eron. JJ, et al. Lancet. 2010;375:396-407..

Download Document

Here is the link to download the presentation.
"Lopinavir -RTV + NVP +"The content belongs to its owner. You may download and print it for personal use, without modification, and keep all copyright notices. By downloading, you agree to these terms.